Literature DB >> 23511775

Half-lives of 221Fr, 217At, 213Bi, 213Po and 209Pb from the 225Ac decay series.

G Suliman1, S Pommé, M Marouli, R Van Ammel, H Stroh, V Jobbágy, J Paepen, A Dirican, F Bruchertseifer, C Apostolidis, A Morgenstern.   

Abstract

The half-lives of (221)Fr, (217)At, (213)Bi, (213)Po, and (209)Pb were measured by means of an ion-implanted planar Si detector for alpha and beta particles emitted from weak (225)Ac sources or from recoil sources, which were placed in a quasi-2π counting geometry. Recoil sources were prepared by collecting atoms from an open (225)Ac source onto a glass substrate. The (221)Fr and (213)Bi half-lives were determined by following the alpha particle emission rate of recoil sources as a function of time. Similarly, the (209)Pb half-life was determined from the beta particle count rate. The shorter half-lives of (217)At and (213)Po were deduced from delayed coincidence measurements on weak (225)Ac sources using digital data acquisition in list mode. The resulting values: T1/2((221)Fr)=4.806 (6) min, T1/2((217)At)=32.8 (3)ms, T1/2((213)Bi)=45.62 (6)min, T1/2((213)Po)=3.708 (8) μs, and T1/2((209)Pb)=3.232 (5)h were in agreement only with the best literature data.
Copyright © 2013 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23511775     DOI: 10.1016/j.apradiso.2013.02.008

Source DB:  PubMed          Journal:  Appl Radiat Isot        ISSN: 0969-8043            Impact factor:   1.513


  9 in total

1.  Branched amphiphilic peptide capsules: cellular uptake and retention of encapsulated solutes.

Authors:  Pinakin Sukthankar; L Adriana Avila; Susan K Whitaker; Takeo Iwamoto; Alfred Morgenstern; Christos Apostolidis; Ke Liu; Robert P Hanzlik; Ekaterina Dadachova; John M Tomich
Journal:  Biochim Biophys Acta       Date:  2014-02-22

2.  Effects of radiation type and delivery mode on a radioresistant eukaryote Cryptococcus neoformans.

Authors:  Igor Shuryak; Ruth A Bryan; Jack Broitman; Stephen A Marino; Alfred Morgenstern; Christos Apostolidis; Ekaterina Dadachova
Journal:  Nucl Med Biol       Date:  2015-03-11       Impact factor: 2.408

Review 3.  An Overview of Targeted Alpha Therapy with 225Actinium and 213Bismuth.

Authors:  Alfred Morgenstern; Christos Apostolidis; Clemens Kratochwil; Mike Sathekge; Leszek Krolicki; Frank Bruchertseifer
Journal:  Curr Radiopharm       Date:  2018

4.  Development of [225Ac]Ac-PSMA-I&T for Targeted Alpha Therapy According to GMP Guidelines for Treatment of mCRPC.

Authors:  Eline L Hooijman; Yozlem Chalashkan; Sui Wai Ling; Figen F Kahyargil; Marcel Segbers; Frank Bruchertseifer; Alfred Morgenstern; Yann Seimbille; Stijn L W Koolen; Tessa Brabander; Erik de Blois
Journal:  Pharmaceutics       Date:  2021-05-13       Impact factor: 6.321

5.  TAG-72-Targeted α-Radionuclide Therapy of Ovarian Cancer Using 225Ac-Labeled DOTAylated-huCC49 Antibody.

Authors:  Megan Minnix; Lin Li; Paul J Yazaki; Aaron D Miller; Junie Chea; Erasmus Poku; An Liu; Jeffrey Y C Wong; Russell C Rockne; David Colcher; John E Shively
Journal:  J Nucl Med       Date:  2020-07-03       Impact factor: 11.082

6.  ²¹³Bi-DOTATOC receptor-targeted alpha-radionuclide therapy induces remission in neuroendocrine tumours refractory to beta radiation: a first-in-human experience.

Authors:  C Kratochwil; F L Giesel; F Bruchertseifer; W Mier; C Apostolidis; R Boll; K Murphy; U Haberkorn; A Morgenstern
Journal:  Eur J Nucl Med Mol Imaging       Date:  2014-07-29       Impact factor: 9.236

7.  Nuclear Data Evaluation for Mass Chain A=217:Odd-Proton Nuclei.

Authors:  Sherif S Nafee; Salem A Shaheen; Amir M Al-Ramady
Journal:  PLoS One       Date:  2016-01-13       Impact factor: 3.240

8.  Targeted alpha therapy of mCRPC: Dosimetry estimate of 213Bismuth-PSMA-617.

Authors:  Clemens Kratochwil; Karl Schmidt; Ali Afshar-Oromieh; Frank Bruchertseifer; Hendrik Rathke; Alfred Morgenstern; Uwe Haberkorn; Frederik L Giesel
Journal:  Eur J Nucl Med Mol Imaging       Date:  2017-09-11       Impact factor: 9.236

Review 9.  Global experience with PSMA-based alpha therapy in prostate cancer.

Authors:  Mike M Sathekge; Frank Bruchertseifer; Mariza Vorster; Alfred Morgenstern; Ismaheel O Lawal
Journal:  Eur J Nucl Med Mol Imaging       Date:  2021-06-26       Impact factor: 9.236

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.